<DOC>
	<DOCNO>NCT00336765</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multiple receptor tyrosine kinase ( RTK ) inhibitor ( include EGFR , VEGFR2 , ErbB2 , EphB4 ) XL647 give orally daily adult advance solid tumor .</brief_summary>
	<brief_title>Study XL647 Administered Orally Daily Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subject histologically confirm malignancy metastatic unresectable Subject disease assessable tumor marker , physical , radiologic mean Subject least 18 year old Subject ECOG performance status ≤ 2 ( Karnofsky ≥ 60 % ) Subject life expectancy ≥ 3 month Subject normal organ marrow function Subject give write informed consent Subject must use accepted method contraception study Female subject childbearing potential must negative pregnancy test Subject receive anticancer treatment within 30 day first dose XL647 Subject receive another investigational agent within 30 day first dose XL647 Subject know brain metastasis Subject correct QT interval ( QTc ) &gt; 0.45 second Subject currently receive anticoagulation therapy warfarin Subject uncontrolled intercurrent illness Subject pregnant breastfeeding Subject know HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>solid tumor</keyword>
</DOC>